Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma

BACKGROUND: There is an urgent need for additional therapies to treat recurrent glioblastoma (GBM). Preclinical studies suggest that high dose macitentan, an oral dual endothelin receptor antagonist, enhances the cytotoxic effects of temozolomide (TMZ) in GBM, improving survival. This phase I trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Weathers, Shiao-Pei, Rood-Breithaupt, Julie, de Groot, John, Thomas, Gail, Manfrini, Marianna, Penas-Prado, Marta, Puduvalli, Vinay K, Zwingelstein, Christian, Yung, W K Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528265/
https://www.ncbi.nlm.nih.gov/pubmed/34693288
http://dx.doi.org/10.1093/noajnl/vdab141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528265/
https://www.ncbi.nlm.nih.gov/pubmed/34693288
http://dx.doi.org/10.1093/noajnl/vdab141

Ejemplares similares